CD8A and malaria: As such, in light of the discovery of a malaria vaccine, selecting antigens that present MHC class I and II epitopes should be prioritized given the mounting evidence that antigen-specific CD8+ and CD4+ immune responses contribute for protection from sporozoite challenge both in animal models and human malaria [42].